Although both of the sensitivity and specificity of NEFL mRNA in predicting the relapse or distant metastasis within five years were not the highest compared with other clinicopathological variables for overall breast cancer patients, the sensitivity of NEFL mRNA was higher than other factors for patients in clinical stage I/II and negative lymph node metastasis stratifications. The gene discussed is NEFL; the disease is breast carcinoma.